Genoscience Pharma Is Innovating to Disrupt Cancer Treatment

We are conceptualizing and developing disruptive and innovative science from bench to bedside for improving the conditions of patients in serious unmet medical needs.

Learn More

Our Approach

As all human living cells, cancer cells need energy to self-renew and survive. Lysosome is a key compartment implicated in cancer cells survival. Among the acquired modifications in cancer cells, changes in lysosomal phenotype and functions are well described, making lysosome a target of interest for novel therapies. Genoscience Pharma focuses on new approaches based on the depriving of cancer cells from essential nutrients by disrupting lysosomal functions.

Discover

Our Pipeline

We leverage our deep knowledge of underlying biological processes to develop innovative and disruptive technology, with potent small molecule drug candidates that directly target lysosomal functions, implicated in the growth, spread and resistance of cancers. We retain global development and commercialization rights of GNS561.

Discover

News

News
7 April 2025

Genoscience Pharma Grants Exclusive Rights to GNS561 to Genfit for Cancer Treatment Development

MARSEILLE-LILLE, April 07, 2025 – Genoscience Pharma has granted Genfit exclusive rights to develop and…
Read More
News
19 April 2023

Genoscience Pharma has announced a new agreement for research at the Hebrew University of Jerusalem on targeted degradation technology

MARSEILLE-JERUSALEM, April 19, 2023 – Genoscience Pharma a clinical-stage biopharmaceutical company that develops disruptive therapeutics…
Read More
News
1 February 2023

ODD obtained by Genoscience Pharma from FDA to treat HCC

Genoscience Pharma receives FDA Orphan Drug Designation for ezurpimtrostat to treat HepatoCellular Carcinoma (HCC) Ezurpimtrostat…
Read More
View All News

Events

Events
13 November 2023

AASLD, The Liver Meeting 2023, Boston, USA

The Scientific Program Committee of the American Association for the Study of Liver Diseases (AASLD)…
Read More
Events
12 January 2023

J.P. Morgan Week – SAN FRANCISCO- 9 to 11 January 2023

J.P. Morgan Healthcare Week 2023 We participated both to the French Healthcare Corner organized by…
Read More
Events
22 April 2022

BIOTRINITY – LONDON – 26-27th April 2022

Genoscience Pharma is enthusiastic, after having selected , about presenting the company  during the Company…
Read More
View All Events

“Translating novel scientific insights into medicines for cancer patients”

Philippe Halfon, CEO of Genoscience Pharma